Boston Tech
Flare Therapeutics Raised $85 Million to Drug Transcription Factors, Which Is Extremely Cambridge
Cambridge-based Flare Therapeutics raised $85 million on June 30 to push a first-in-class prostate cancer program after years of transcription-factor homework.